Neuraxpharm is pursuing growth strategy for business in Switzerland
The leading European specialist company for the central nervous system is expanding its activities in the highly attractive Swiss market and is introducing Jörg Gärtner as the new Country Manager
Düsseldorf and Liestal, May 3, 2022 – The Neuraxpharm Group (Neuraxpharm) ignites the next stage of its business in Switzerland to realize the full potential of the important pharmaceutical market. Having recently laid the foundation for its Swiss business, Neuraxpharm is strengthening its commitment to the market with the appointment today of Jörg Gärtner as Country Manager for Switzerland. As an experienced executive, Jörg Gärtner will focus on the further development of Neuraxpharm as a specialist for the central nervous system (CNS) in the Swiss market.
Due to its excellent public health system and its high purchasing power, Switzerland represents an attractive pharmaceutical market in Europe. Neuraxpharm is tapping into this market potential with its product range for CNS drugs. The company will leverage its CNS expertise to provide access to eligible products from its extensive portfolio, including recently acquired Buccolam® for the emergency treatment of children and adolescents with epilepsy. Neuraxpharm entered the market in 2019 through the acquisition of STU, a leading Swiss-based distributor of consumer cannabidiol (CBD) products. Neuraxpharm also plans to launch its medical cannabis portfolio over the next few months to meet increasing demand in the booming market.
With Jörg Gärtner, Neuraxpharm can rely on a committed pharmaceutical leader with highly relevant market expertise. With more than 25 years of experience in the pharmaceutical industry, he gained profound knowledge of different countries, companies and different therapeutic indications. Jörg Gärtner has a strong track record of successfully launching innovative products in competitive markets such as Germany, Austria and Switzerland. At Neuraxpharm, he will use this knowledge to further expand the company’s market share in Switzerland and ensure the successful expansion of the product portfolio, for example with medical cannabis.
Jörg Gärtner comes to Neuraxpharm from Almirall, where he most recently worked as Business Leader Neurology in the CHAT division. Prior to his appointment as Business Leader, he was Head of Global Marketing for Sativex®. Jörg Gärtner was Brand Lead/Product Manager for Tecfidera® from 2012 to 2016 at Biogen Switzerland, having previously held positions in product management at Roche Pharma Germany from 1996 to 2012. He started his career from 1992 to 1996 as a Primary Care Sales Representative at Lilly Germany and holds a Masters in International Economics from Paris-Dauphine University and a Masters in General Management from the Technical University of Berlin.
dr Jörg-Thomas Dierks, CEO of Neuraxpharm, stated: “The Swiss market is of great strategic importance for Neuraxpharm. Having entered the market relatively recently through the acquisition of STU and their CBD portfolio, we are now very confident that with Jörg Gärtner we will successfully take our Swiss business to the next level due to his extensive experience and his entrepreneurial mindset, Jörg is well-placed to capitalize on growth opportunities in the CNS and medicinal cannabis markets.”
Jörg Gärtner, newly appointed Country Manager for Switzerland, adds: “I am very pleased to join Neuraxpharm as Country Manager. Neuraxpharm is in the perfect position to successfully expand into the Swiss market – in CNS products and beyond. I look forward to working with my new team and making my expertise available both in pharma and industry as well as in Switzerland.”